Full Title
A Phase II Study of Time-limited Combination of Pirtobrutinib, Venetoclax, and Rituximab in Treatment Naïve Patients with Waldenström’s Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) (PRoVen)Purpose
Researchers want to see how well pirtobrutinib, venetoclax, and rituximab work together in people with Waldenström’s macroglobulinemia (WM) who have not been previously treated. WM is a type of lymphoma, namely lymphoplasmacytic lymphoma (LPL). This slow-growing cancer affects white blood cells called B lymphocytes.
Pirtobrutinib works by blocking a protein called BTK, which helps cancer cells grow and survive. By blocking this protein, pirtobrutinib may help stop cancer cells from growing and spreading. It is taken orally (by mouth).
Venetoclax blocks BCL-2, a protein in cancer cells that helps them survive and resist the effects of cancer treatments. Venetoclax may kill cancer cells or make them more sensitive to other treatments. It is also taken orally.
Rituximab binds to the CD20 protein on B cells and cancer cells. This binding action helps the immune system kill cancer cells. Rituximab is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have WM/LPL that has not yet been treated.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information about this study or to see if you can join, please call Dr. Lia Palomba’s office at 646-608-3711.